Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans.
The bioavailability of clofibric acid from formulations containing calcium clofibrate along and mixed with calcium carbonate (1:1 w/w) was compared to that from a standard clofibrate formulation in a crossover study in 12 human subjects. The 95% confidence intervals of bioavailability differences were such that  they were unlikely to be detected in  clinical practice; all three formulations may be considered bioequivalent, although the bioavailability rate was probably greater from the formulation containing calcium clofibrate alone. Peaks of mean concentrations of 80 +/- 13,67 +/- 16, and 64 +/- 18 microgram/ml +/- SD occurred after administration of 853 mg of clofibric acid calcium salt alone, 809 mg of clofibric acid calcium salt mixed with calcium carbonate, and 885 mg of clofibrate, respectively; mean concentrations declined from peak levels with half-lives of 15-17 hr.
D000328:Adult; D001682:Biological Availability; D002118:Calcium; D002119:Calcium Carbonate; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D002994:Clofibrate / Q000008:administration & dosage / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D002214:Capsules; D002119:Calcium Carbonate; D002994:Clofibrate; D002118:Calcium